PPARγ LIGAND SUPPRESSES FOXP3 EXPRESSION IN T-REGULATORY CELLS DURING EXCESSIVE INFLAMMATION VIA MODULATING HISTONE ACETYLTRANSFERASE AND HDAC6/11 ACTIVITIES

Received 2022-06-15; Accepted 2022-09-10; Published 2022-12-31

Authors

  • Nor Effa Syazuli Zulkafli Department of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200, Bertam, Kepala Batas, Penang, Malaysia.
  • Lee Pei Chen Complex E, Centre for Administration Federal Government, Ministry of Health, Malaysia, 62590, Putrajaya, Malaysia.
  • Norazmi Mohd Nor School of Health Sciences, Universiti Sains Malaysia, Health Campus, 12150 Kubang Kerian, Kelantan, Malaysia.

DOI:

https://doi.org/10.22452/jummec.sp2022no1.7

Abstract

Natural T-Regulatory (nTreg) cells represent approximately 8-10% of the total CD4+ T cell population and constantly expressing Foxp3 proteins. These cells are crucial for immune homeostasis, preventing over-inflammation and autoimmunity. Our previous study reported that PPARγ ligand, 15d-PGJ2 negatively influences the expression of Foxp3 in nTreg cells, which reflexes the attenuation in immunosuppressive function of nTreg cells. This study aims to unveil the molecular mechanism of Foxp3 suppression by PPARγ in nTreg cells during autoimmune Type 1 Diabetes. Co-stimulatory proteins were measured using flow cytometry and methylation measurement of Foxp3 expression was measured based on histone modification activity. Nuclear proteins of isolated cells were extracted out to measure two HDAC and two HAT enzyme activities using ELISA. Purified nTreg cells were isolated using MoFlow Cell sorter, and will be then cultured for 72 hrs to mimic the TCR activation and downstream signalling. The expression of Foxp3 in these cells were measured using flow cytometry analysis and were positively selected. Current data showed that histone acetylation activities were cross talked with PPARγ pathway in nTreg cells from diabetic, but in healthy mice. FoxP3 gene expression may be regulated via histone modification that in diabetic mice via PPARγ- independent pathways. Altogether, this study provides fundamental analysis on the putative role of PPARγ ligand 15d-PGJ2 as HDAC6/11 inhibitors. Therefore, this may suggest that combination of 15d-PGJ2 and GW9662 can be an alternative to HDAC6 inhibitor which is less toxic compared to pan-HDACi in treating inflammatory-related diseases. These ligands also potentially able to suppress the microenvironment of nTreg cells protecting tumour-bearing cells.

Downloads

Download data is not yet available.

Downloads

Published

2022-12-31